- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Crisis Management
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Gillian M. Russell
Insights 13 results
Client Alert
January 23, 2023
2022 Year in Review: FDA Drug and Device Advertising and Promotion Enforcement
Article · Source: Chambers and Partners
March 21, 2022
Chambers Global Practice Guide: Pharmaceutical Advertising 2022
Client Alert
August 6, 2021
FDA Finalizes “Intended Use” Regulations
Article · Source: Chambers and Partners
March 19, 2021
Pharmaceutical Advertising
Client Alert
September 24, 2020
FDA Proposes New Rule Modifying its “Intended Use” Regulations
Article · Source: Chambers and Partners
March 2, 2020
Chambers Global Practice Guide: Pharmaceutical Advertising
Client Alert
January 26, 2017
FDA Defends Its First Amendment Position in “Memorandum”
Client Alert
January 20, 2017
FDA Issues Draft Guidance Addressing Communications with Payors
Client Alert
January 19, 2017
FDA Takes Action in the Last Days of the Obama Administration to Clarify Some of Its Views on Off-Label Communications
Article
March 17, 2016
2015 Year in Review: Drug Promotion Warning Letters
Client Alert
March 8, 2016
2015 Year in Review: OPDP and APLB Warning and Untitled Letters
Client Alert
February 10, 2015
FDA Revises Approach to Presentation of Risk Information in Brief Summary